Indivior PLC (NASDAQ:INDV - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $12.86, but opened at $12.58. Indivior shares last traded at $12.46, with a volume of 212,763 shares traded.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler lowered their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th.
View Our Latest Stock Analysis on INDV
Indivior Trading Up 7.8%
The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -39.06 and a beta of 0.98. The business's 50 day moving average price is $10.61 and its two-hundred day moving average price is $10.80.
Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. Analysts expect that Indivior PLC will post 1.22 EPS for the current year.
Institutional Trading of Indivior
A number of hedge funds have recently made changes to their positions in INDV. Deerfield Management Company L.P. Series C raised its holdings in Indivior by 74.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after buying an additional 3,790,518 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company's stock worth $9,327,000 after purchasing an additional 958,132 shares during the period. Claret Asset Management Corp bought a new stake in shares of Indivior in the fourth quarter worth $9,304,000. Finally, Acadian Asset Management LLC acquired a new stake in Indivior in the first quarter valued at $6,328,000. 60.33% of the stock is owned by institutional investors and hedge funds.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
